Skip to content

Accurate WiFi-Based Localization of Dementia Patients For Caregiver Support:

Accurate WiFi-Based Localization of Dementia Patients For Caregiver Support: Phase II

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03360019
Enrollment
13
Registered
2017-12-02
Start date
2021-01-27
Completion date
2022-05-31
Last updated
2023-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Dementia, Dementia, Vascular, Lewy Body Dementia With Behavioral Disturbance

Brief summary

In this Phase II SBIR project we will enhance a wireless WiFi-based insole that was designed and successfully tested during a Phase I trial with elderly persons with dementia and their caregivers, and then investigate its efficacy in terms of caregiver activity, burden, and quality of life in Phase II. Evaluation will use semi-structured interviews and participant observation data collected from professional and family caregivers of patients with moderate or mild dementia.

Detailed description

The efficacy of the Activlink system offering localization information to improve caregiver will be evaluated in two studies. Study 2a will use the insole system with dementia patients residing in skilled or memory care. Data regarding caregiving activity will be collected from their paid professional care providers. Study 2b will use participant localization data collected on 80 independently dwelling mild dementia patients. In this case data will be collected from their unpaid family caregivers. Both studies will result in evaluating the efficacy of the WiFi-based insole to provide caregivers with augmented patient awareness, helping to improve their immediate quality of life by reducing their direct burden of continuous oversight of their person in care.

Interventions

DEVICEActivlink insole

Dementia patients will wear the provided insole inserted into their own shoes. The insole will have a small electronic sensor that measures acceleration, foot force, and/or orientation.

OTHERActivlink Phone Application

Smartphone tool used for monitoring location

Sponsors

National Institute on Aging (NIA)
CollaboratorNIH
Aster Labs, Inc
CollaboratorUNKNOWN
University of Florida
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Counterbalanced within-subject design. Specifically, each target patient will randomly be assigned to either have the technology or not have the technology applied for a period of three months, followed by three months of the opposite condition. Caregivers will provide caregiver ratings twice monthly during these two epochs.

Eligibility

Sex/Gender
ALL
Age
21 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

Persons With Dementia Resides in memory care or skilled nursing * Moderate dementia (MMSE of 10-18) * Ambulatory (without or with cane, walker or wheelchair assist) * A legal proxy that can provide consent Persons With Dementia Resides in independent living setting in community. * Mild dementia (MMSE of 19-25) * Ambulatory (without or with cane, walker or wheelchair assist). * Has a legal proxy that can provide consent. Care Partners * Speaks English * Be 21 years of age or over * Has at least three times per week direct contact with person with dementia (PWD) * Consents to participate in the study

Exclusion criteria

* Is not fluent in written or spoken English * Indicate an unwillingness to use the Activlink * History of Major Mental Illness for patient or caregiver

Design outcomes

Primary

MeasureTime frameDescription
Caregiver Activity Surveyweek 2Validated scale requires caregivers to report on amount of time spent caregiving for a particular patient. It has high test-retest reliability. Caregivers will be asked to complete this instrument once every two weeks. The scale describes the total number of minutes spent daily on six different caregiving activities. Therefore the minimum value for each item is 0 and the maximum is 1,440 for each item. Higher scores on each item mean more time spent caregiving.

Secondary

MeasureTime frameDescription
Zarit Caregiver Burden ScaleUp to 6 monthsThis is validated instrument designed to reflect what people sometimes feel when taking care of another person. Caregivers will be asked to complete this instrument once every two weeks. Total score was calculated. Scores ranged from 0-48 with a higher score indicating greater caregiver burden.
AD Quality of Life Scaleup to 6 monthsAssesses Caregiver quality of life with 13 questions rating from poor to excellent. Caregivers circle their responses. Caregivers will be asked to complete this instrument once every two weeks. Total score was calculated. Scores ranged from 13-52, with a higher score indicating better quality of life in caregivers.

Other

MeasureTime frameDescription
Device AccuracyFirst month of overall study periodPercentage of physical checks where device displayed correct location of patient/resident. Only partners reported on the accuracy. No data were required from participants. Therefore, they were entered as 0s in the chart.

Countries

United States

Participant flow

Participants by arm

ArmCount
Residents in Memory Care or Skilled Nursing Facility
Activlink insole: Dementia patients will wear the provided insole inserted into their own shoes. The insole will have a small electronic sensor that measures acceleration, foot force, and/or orientation.
10
Resident in Independent Living Setting
Activlink insole: Dementia patients will wear the provided insole inserted into their own shoes. The insole will have a small electronic sensor that measures acceleration, foot force, and/or orientation.
0
Care Partners
Activlink Phone Application: Smartphone tool used for monitoring location
3
Total13

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyPandemic caused suspension of study activities600
Overall StudyWithdrawal by Subject200

Baseline characteristics

CharacteristicResidents in Memory Care or Skilled Nursing FacilityCare PartnersTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
9 Participants0 Participants9 Participants
Age, Categorical
Between 18 and 65 years
1 Participants3 Participants4 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
10 Participants3 Participants13 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
MiniMental State Exam18.8 units on a scale
STANDARD_DEVIATION 3.8
18.8 units on a scale
STANDARD_DEVIATION 3.8
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
10 Participants3 Participants13 Participants
Region of Enrollment
United States
10 participants3 participants13 participants
Sex: Female, Male
Female
7 Participants3 Participants10 Participants
Sex: Female, Male
Male
3 Participants0 Participants3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 00 / 3
other
Total, other adverse events
1 / 100 / 00 / 3
serious
Total, serious adverse events
0 / 100 / 00 / 3

Outcome results

Primary

Caregiver Activity Survey

Validated scale requires caregivers to report on amount of time spent caregiving for a particular patient. It has high test-retest reliability. Caregivers will be asked to complete this instrument once every two weeks. The scale describes the total number of minutes spent daily on six different caregiving activities. Therefore the minimum value for each item is 0 and the maximum is 1,440 for each item. Higher scores on each item mean more time spent caregiving.

Time frame: week 2

Population: TIme reported by professional care giver spent in caring for monitored resident

ArmMeasureValue (MEAN)Dispersion
Care PartnersCaregiver Activity Survey305.7 minutesStandard Deviation 177.5
Secondary

AD Quality of Life Scale

Assesses Caregiver quality of life with 13 questions rating from poor to excellent. Caregivers circle their responses. Caregivers will be asked to complete this instrument once every two weeks. Total score was calculated. Scores ranged from 13-52, with a higher score indicating better quality of life in caregivers.

Time frame: up to 6 months

Population: No data were collected for this measure because nurse practitioners failed to complete the biweekly survey.

Secondary

Zarit Caregiver Burden Scale

This is validated instrument designed to reflect what people sometimes feel when taking care of another person. Caregivers will be asked to complete this instrument once every two weeks. Total score was calculated. Scores ranged from 0-48 with a higher score indicating greater caregiver burden.

Time frame: Up to 6 months

Population: No data were collected for this measure because the nurse practitioners failed to respond to the surveys biweekly.

Other Pre-specified

Device Accuracy

Percentage of physical checks where device displayed correct location of patient/resident. Only partners reported on the accuracy. No data were required from participants. Therefore, they were entered as 0s in the chart.

Time frame: First month of overall study period

Population: In validation phase of study, Nursing assistants were sent intermittent prompts to compare location of resident as indicated by the device to actual physical location of patient as determined by direct observation.

ArmMeasureValue (NUMBER)
Residents in Memory Care or Skilled Nursing FacilityDevice Accuracy87.83 percentage of observations

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026